Rob Gietl, CEO of MYM Nutraceuticals, focus cannabis company in the medical industry.
MYM is a integrated cannabis company with the prime directive of our business plan.
We were going off business models that we’ve seen in the U.S.
More important, we’re here for the long-term and more stability in that category.
One is the development of seed and live tissue culture. Furthersome which we can sell through a variety of different seed banks around the world.
And sell for ourselves through two things, first, one is to keep the quality of the product. And make sure that we do not have any gaps in our production schedule.
We also have many large grows in Canada and abroad. We produce flower for and we have the capability of doing extraction down to oil.
Also, have a manufacturing facility that’s on its final stages of completion right now. It allows us to produce final consumables in the forms of transdermal patches.
RND and various developments in countries are fascinating. They are growing on daily basis and medical responses.